Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy
- PMID: 37142904
- PMCID: PMC11286621
- DOI: 10.1007/s10803-023-05941-8
Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy
Abstract
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.
Keywords: Autism; Children; Cost-effectiveness; Epilepsy; Family impacts; Healthcare expenditure.
© 2023. The Author(s).
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Prof Murphy has been a consultant to or has received honoraria or grants from Servier, Roche, Clinical Research Associates, and Jaguar Theraputics. He has also received funding from the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 777394, Project AIMS-2-TRIALS).
Figures
Similar articles
-
Costing of antiepileptic drugs.Lancet. 1996 Jan 27;347(8996):266. doi: 10.1016/s0140-6736(96)90443-2. Lancet. 1996. PMID: 8551913 No abstract available.
-
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134. doi: 10.3310/hta11370. Health Technol Assess. 2007. PMID: 17903391 Clinical Trial.
-
If comparisons can be odious, so can assumptions.Seizure. 1996 Sep;5(3):247-8. doi: 10.1016/s1059-1311(96)80045-8. Seizure. 1996. PMID: 8902930 No abstract available.
-
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.Seizure. 1995 Mar;4(1):37-44. doi: 10.1016/s1059-1311(05)80076-7. Seizure. 1995. PMID: 7788105 Review.
-
[Analysis of cost minimization of monotherapy antiepileptic treatment in patients with recent diagnosed epilepsy : the situation in Spain].Rev Neurol. 2000 Nov 1-15;31(9):828-32. Rev Neurol. 2000. PMID: 11127083 Review. Spanish.
Cited by
-
Evaluating Parents' Concerns, Needs, and Levels of Satisfaction with the Services Provided for ASD Children in Saudi Arabia.J Multidiscip Healthc. 2024 Jan 8;17:123-146. doi: 10.2147/JMDH.S447151. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38222477 Free PMC article.
References
-
- Almathami, H., Win, K. T., & Vlahu-Gjorgievska, E. (2020). Barriers and facilitators that influence Telemedicine-Based, Real-Time, Online Consultation at Patients’ Homes: systematic literature review. Journal of medical Internet research, 22(2), e16407. 10.2196/16407 10.2196/16407 - DOI - PMC - PubMed
-
- Autistica (2022). Make the most of a telephone health appointment. Retrieved October 15 h 2021 from https://www.autistica.org.uk/what-is-autism/coronavirus/make-the-most-of...
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical